title: Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients.
abstract: BACKGROUND
  Excessive mast cell mediator release may lead to anaphylaxis in patients with mastocytosis. However, the incidence, clinical features and trigger factors have not yet been analyzed.
  
  
  METHODS
  To identify risk factors for anaphylaxis in mastocytosis, we determined cumulative incidence, severity, clinical characteristics, and trigger factors for anaphylaxis in 120 consecutive patients (53 male; 67 female, median age and range 24 years, 1 month to 73 years), and correlated these with disease severity of mastocytosis, skin involvement, basal total serum tryptase, and diaminooxidase concentrations.
  
  
  RESULTS
  The cumulative incidence of anaphylaxis in patients with mastocytosis was higher in adults (49%; P < 0.01) compared with that in children (9%). Only children with extensive skin involvement had experienced anaphylaxis. In adults, anaphylaxis was correlated to the absence of urticaria pigmentosa lesions (P < 0.03). Reactions occurred more frequently in adults with systemic (56%) when compared with cutaneous mastocytosis (13%; P < 0.02). In adults, 48% of reactions were severe, and 38% resulted in unconsciousness. Major perceived trigger factors for adults were hymenoptera stings (19%), foods (16%), and medication (9%); however, in 26% of reactions, only a combination of different triggers preceded anaphylaxis. Trigger factors remained unidentified in 67% of reactions in children compared with 13% in adults. Patients with anaphylaxis had higher basal tryptase values (60.2 +/- 55 ng/ml, P < 0.0001) in comparison with those without (21.2 +/- 33 ng/ml), but not diaminooxidase levels.
  
  
  CONCLUSIONS
  Adult patients and children with extensive skin disease with mastocytosis have an increased risk to develop severe anaphylaxis; thus, an emergency set of medication including epinephrine is recommended.
authors.affiliation: Department of Dermatology and Allergy Biederstein, Technical University Munich, Munich, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Brockow
authors.forename: C
authors.initials: C
authors.lastname: Jofer
authors.forename: H
authors.initials: H
authors.lastname: Behrendt
authors.forename: J
authors.initials: J
authors.lastname: Ring
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000707:Anaphylaxis / Q000453:epidemiology* / Q000209:etiology / Q000276:immunology / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D008415:Mastocytosis / Q000150:complications / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology; D034701:Mastocytosis, Cutaneous / Q000150:complications / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology; D034721:Mastocytosis, Systemic / Q000150:complications / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology; D008875:Middle Aged; D012307:Risk Factors; D012720:Severity of Illness Index; D053802:Tryptases / Q000097:blood
chemical_list: D053802:Tryptases